Trial Profile
Prospective single-centre study investigating the single nucleotide polymorphisms (SNPs) occurring in patients with metastatic breast cancer treated with Everolimus (EVE) and Exemestane (EXE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Pharmacokinetics
- 09 Feb 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium